These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 35887189)

  • 21. Integrating the contributions of mitochondrial oxidative metabolism to lipotoxicity and inflammation in NAFLD pathogenesis.
    Hughey CC; Puchalska P; Crawford PA
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Nov; 1867(11):159209. PubMed ID: 35934297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH).
    Takaki A; Kawai D; Yamamoto K
    Int J Mol Sci; 2014 Apr; 15(5):7352-79. PubMed ID: 24786095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
    Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
    Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental models of non-alcoholic fatty liver disease in rats.
    Kucera O; Cervinkova Z
    World J Gastroenterol; 2014 Jul; 20(26):8364-76. PubMed ID: 25024595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macrophages and scavenger receptors in obesity-associated non-alcoholic liver fatty disease (NAFLD).
    Kragh Petersen S; Bilkei-Gorzo O; Govaere O; Härtlova A
    Scand J Immunol; 2020 Nov; 92(5):e12971. PubMed ID: 32892401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-alcoholic fatty liver disease.
    Leclercq I
    Bull Mem Acad R Med Belg; 2010; 165(3-4):147-55; discussion 155-8. PubMed ID: 21166266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty Liver Disease.
    Zhou Y; Li Z; Xu M; Zhang D; Ling J; Yu P; Shen Y
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
    Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
    Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis.
    Branković M; Jovanović I; Dukić M; Radonjić T; Oprić S; Klašnja S; Zdravković M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of non-coding RNAs on liver metabolism and NAFLD pathogenesis.
    Qian G; Morral N
    Hum Mol Genet; 2022 Oct; 31(R1):R4-R21. PubMed ID: 35417923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promising therapies for treatment of nonalcoholic steatohepatitis.
    Noureddin M; Zhang A; Loomba R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.
    Lim JW; Dillon J; Miller M
    World J Gastroenterol; 2014 Jul; 20(26):8325-40. PubMed ID: 25024592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GDF11 induces mild hepatic fibrosis independent of metabolic health.
    Frohlich J; Kovacovicova K; Mazza T; Emma MR; Cabibi D; Foti M; Sobolewski C; Oben JA; Peyrou M; Villarroya F; Soresi M; Rezzani R; Cervello M; Bonomini F; Alisi A; Vinciguerra M
    Aging (Albany NY); 2020 Oct; 12(20):20024-20046. PubMed ID: 33126224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease.
    Lefere S; Van de Velde F; Devisscher L; Bekaert M; Raevens S; Verhelst X; Van Nieuwenhove Y; Praet M; Hoorens A; Van Steenkiste C; Van Vlierberghe H; Lapauw B; Geerts A
    Int J Obes (Lond); 2017 Aug; 41(8):1207-1213. PubMed ID: 28461687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological Mechanisms and Related Natural Inhibitors of CD36 in Nonalcoholic Fatty Liver.
    Feng Y; Sun W; Sun F; Yin G; Liang P; Chen S; Liu X; Jiang T; Zhang F
    Drug Des Devel Ther; 2022; 16():3829-3845. PubMed ID: 36388082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current treatment of non-alcoholic fatty liver disease.
    Paternostro R; Trauner M
    J Intern Med; 2022 Aug; 292(2):190-204. PubMed ID: 35796150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.